Overview

Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

This is a randomized study to evaluate the efficacy and safety neoadjuvant androgen deprivation therapy with goserelin and abiraterone with or without apalutamide prior to radical prostatectomy for patients diagnosed with localized high-risk prostate cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Instituto do Cancer do Estado de São Paulo

Collaborator:

Janssen, LP

Treatments:

Androgens
Goserelin
Prednisone